Cellceutix Corp.(CTIX)- OTCQB
  • Sep. 16, 2013, 8:08 AM
    • Cellceutix Corporation (CTIX.OB) says it will "immediately advance" Brilacidin — the defensin-mimetic antibiotic acquired in the recent deal for PolyMedix — to a Phase 2b clinical trial for acute bacterial skin and skin structure infections.
    • The company also says the compound may be effective for oral mucositis and as such, CTIX plans to finalize an IND and pursue an orphan designation for the treatment.
    • Ultimately, the company sees quite a few exciting opportunities for the assets acquired from PolyMedix: "We believe we hit a home run with the PolyMedix acquisition, especially as it pertains to Brilacidin. The reality of owning these assets is now beginning to set in." (PR)
    • More on Brilacidin here
    | Sep. 16, 2013, 8:08 AM